If you have been reading about copper(II) centre and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-19. Numbers and descriptions here follow the published literature rather than marketing material.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Coordination compound rather than a simple salt |
| Peptide sequence | Glycyl-L-histidyl-L-lysine | Abbreviated GHK in most literature |
| Molecular formula | C14H22N6O4Cu | Reported for the 1:1 complex |
| Principal binding site | Histidine imidazole nitrogen | Backbone amides contribute additional coordination |
| Common synonym | Copper tripeptide-1 | Used in ingredient and product labelling |
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
Stability of the complex in solution depends on pH, temperature, and the presence of competing ligands. It is generally described as more resistant to breakdown than the metal-free chain, since coordination reduces susceptibility to enzymatic attack. Oxidation and hydrolysis can nevertheless proceed over time in aqueous media. Storage guidance in laboratory settings commonly involves refrigeration, protection from light, and avoidance of strongly alkaline conditions. Published data on long-term behaviour vary considerably and depend on the specific matrix.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
=== Evaluation === The thyroid is examined by observation of the gland and surrounding neck for swelling or enlargement. It is then felt, usually from behind, and a person is often asked to swallow to better feel the gland against the fingers of the examiner. The gland moves up and down with swallowing because of its attachments to the thyroid and cricoid cartilages. In a healthy person the gland is not visible yet is palpable as a soft mass. Examination of the thyroid gland includes the search for abnormal masses and the assessment of overall thyroid size. The character of the thyroid, swellings, nodules, and their consistency may all be able to be felt. If a goitre is present, an examiner may also feel down the neck consider tapping the upper part of the chest to check for extension. Further tests may include raising the arms (Pemberton's sign), listening to the gland with a stethoscope for bruits, testing of reflexes, and palpation of the lymph nodes in the head and neck. An examination of the thyroid will also include observation of the person as a whole, to look for systemic signs such as weight gain or loss, hair loss, and signs in other locations – such as protrusion of the eyes or swelling of the calves in Graves' disease.
A mimotope is often a peptide, and mimics the structure of an epitope. Because of this property it causes an antibody response similar to the one elicited by the epitope. An antibody for a given epitope antigen will recognize a mimotope which mimics that epitope. Mimotopes are commonly obtained from phage display libraries through biopanning. Vaccines utilizing mimotopes are being developed. Mimotopes are a kind of peptide aptamers. When the term mimotope was coined by Mario Geysen in 1986, it was used to describe peptides mimicking epitopes. However, this concept has been extended to refer peptide mimic of all types of binding sites. As the mimic of binding site, mimotope analysis has been widely used in mapping epitopes, identifying drug target and inferring protein interaction networks. Furthermore, mimotope has also shown its potential in the development of new diagnostics, therapeutics and vaccines. In addition, special affinities mediated by mimotopes to various semiconductors and other materials have shown very encouraging promise in new material and new energy studies. Gathering information on mimotopes into a special database therefore deserves. In 2010, the MimoDB database version 1.0 was released. It had 10716 peptides grouped into 1229 sets. These peptides were extracted from biopanning results of phage-displayed random peptide libraries reported in 571 papers. The MimoDB database has been updated to the current version 2.0 very recently. In version 2.0, it has 15633 peptides collected from 849 papers and grouped into 1818 sets.
==== Structured breast prosthesis ==== The fourth category of prosthetic-breast technology is the structured breast-prosthesis, which was approved for breast surgery by the Food and Drug Administration in the U.S. and by Health Canada in Canada in 2014. As a medical device, the structured prosthetic-breast incorporates the technologies of saline-solution and of silicone-gel to achieve anatomical function and aesthetic symmetry. Technologically, the internal structure of the breast prosthesis is composed of three, nested shells (made of silicone rubber) that support the upper half of the breast hemisphere; the two spaces between the three nested shells is filled with saline solution. To implant a structured breast prosthesis, the plastic surgeon emplaces the folded, empty prosthetic breast into the implant-socket, then fills the prosthetic breast with saline solution, and afterwards sutures shut the insertion incision.
SCD is most prevalent in areas in which malaria has historically been endemic. The sickle cell trait gives carriers a survival advantage against malaria fatality over people with normal haemoglobin in regions where malaria is endemic. Infection with the malaria parasite affects asymptomatic carriers of the abnormal haemoglobin gene differently from people with full sickle cell disease. Carriers (heterozygous for the gene) who catch malaria are less likely to suffer from severe symptoms than people with normal haemoglobin. People with sickle cell disease (homozygous for the gene) are similarly less likely to become infected with malaria; however, once infected, they are more likely to develop severe and life-threatening anaemia. The impact of sickle cell anaemia on malaria immunity illustrates some evolutionary trade-offs that have occurred because of endemic malaria. Although the shorter life expectancy for those with the homozygous condition would tend to disfavour the trait's survival, the trait is preserved in malaria-prone regions because of the benefits provided by the heterozygous form; an example of natural selection. Due to the adaptive advantage of the heterozygote, the disease is still prevalent, especially among people with recent ancestry in malaria-stricken areas, such as Africa, the Mediterranean, India, and the Middle East. Malaria was historically endemic to southern Europe, but it was declared eradicated in the mid-20th century, except rare sporadic cases. The malaria parasite has a complex lifecycle and spends part of it in red blood cells.
For most of the Lower Paleolithic, human societies were possibly more hierarchical than their Middle and Upper Paleolithic descendants, and probably were not grouped into bands, though during the end of the Lower Paleolithic, the latest populations of the hominin Homo erectus may have begun living in small-scale (possibly egalitarian) bands similar to both Middle and Upper Paleolithic societies and modern hunter-gatherers. Middle Paleolithic societies, unlike Lower Paleolithic and early Neolithic ones, consisted of bands that ranged from 20 to 30 or 25–100 members and were usually nomadic. These bands were formed by several families. Bands sometimes joined into larger "macrobands" for activities such as acquiring mates and celebrations or where resources were abundant. By the end of the Paleolithic era (c. 10,000 BP), people began to settle down into permanent locations, and began to rely on agriculture for sustenance in many locations. Much evidence exists that humans took part in long-distance trade between bands for rare commodities (such as ochre, which was often used for religious purposes such as ritual) and raw materials, as early as 120,000 years ago in Middle Paleolithic. Inter-band trade may have appeared during the Middle Paleolithic because trade between bands would have helped ensure their survival by allowing them to exchange resources and commodities such as raw materials during times of relative scarcity (i.e. famine, drought). Like in modern hunter-gatherer societies, individuals in Paleolithic societies may have been subordinate to the band as a whole.
Sources: en.wikipedia.org
DisplayPort 2.1 has tightened its alignment with the USB Type-C specification as well as the USB4 PHY specification to facilitate a common PHY servicing both DisplayPort and USB4. In addition, DisplayPort 2.1 has added a new DisplayPort bandwidth management feature to enable DisplayPort tunnelling to coexist with other data traffic more efficiently over the USB4 link.
Phenobarbital, sold under the brand name Luminal among others, is a medication of the barbiturate type. It is recommended by the World Health Organization (WHO) for the treatment of certain types of epilepsy in developing countries. In the developed world, it is commonly used to treat seizures in young children, while other medications are generally used in older children and adults. It is also used for veterinary purposes. It may be administered by slow intravenous infusion (IV infusion), intramuscularly (IM), or orally (swallowed by mouth). Subcutaneous administration is not recommended. The injectable forms may be used to treat status epilepticus if other drugs fail to achieve satisfactory results. Phenobarbital is occasionally used to treat insomnia, anxiety, and benzodiazepine withdrawal (as well as withdrawal from certain other drugs in specific circumstances), and prior to surgery as an anxiolytic and to induce sedation. It usually begins working within five minutes when used intravenously and half an hour when administered orally. Its effects last for between four hours and two days. Potentially serious side effects include a decreased level of consciousness and respiratory depression. There is potential for both abuse and withdrawal following long-term use. It may also increase the risk of suicide. It is pregnancy category D in Australia, meaning that it may cause harm when taken during pregnancy. If used during breastfeeding it may result in drowsiness in the baby. Phenobarbital works by increasing the activity of the inhibitory neurotransmitter GABA.
===== Recreational drugs ===== The data on the use of marijuana during breastfeeding is limited; however, in part due to our lack of knowledge in this area, the CDC recommends against using marijuana or marijuana-containing products, including CBD, during breastfeeding. The main active ingredient in marijuana, tetrahydrocannabinol (THC), can be found in breastmilk anywhere from six days to more than six weeks after marijuana use. There is limited data on the long term effects of this exposure on the infant, however some studies have voiced concern regarding delayed motor development in infants exposed to THC.
==== 1996–1997: Appointment and first season ==== In August 1996, Arsenal dismissed Bruce Rioch as club manager. Rioch's position had become untenable after a dispute with the board over transfers, and his working relationship with Dein worsened during the course of his tenure. Arsenal appointed Stewart Houston and later Pat Rice in temporary charge of the first team, while they searched for a full-time successor. Although Barcelona player and manager Johan Cruyff was favourite to take over, the board looked elsewhere, eventually backing Dein's proposal to hire Wenger. The appointment was delayed for several weeks as Wenger was under contract at Nagoya Grampus and the club wanted time to make a final decision. In the meantime, the Arsenal board refused to confirm the identity of their next manager, but speculation grew that it would be Wenger once the club signed French midfielders Patrick Vieira and Rémi Garde. On 22 September 1996, Wenger was unveiled as Arsenal manager, after Nagoya Grampus granted him his release. He officially assumed the role on 1 October 1996, becoming the first Frenchman to manage in the Premier League. At his first press conference, he told reporters: "The main reason for coming is that I love English football, the roots of the game are here. I like the spirit round the game and at Arsenal I like the spirit of the club and its potential."
Present-day Ningxia is one of the nation's smallest provincial-level units and borders the provinces of Shaanxi and Gansu and the Inner Mongolia Autonomous Region. At 3556 meters above sea level, Aobaogeda (敖包疙瘩) in the Helan Mountains is the highest point in Ningxia. Ningxia is a relatively dry, desert-like region and features a diverse geography of forested mountains and hills, table lands, deserts, flood plains and basins cut through by the Yellow River. The Ningxia ecosystem is one of the least studied regions in the world. Significant irrigation supports the growing of wolfberries, a commonly consumed fruit throughout the region. Ningxia's deserts include the Tengger Desert in Shapotou. The northern section, through which the Yellow River flows, supports the best agricultural land. A railroad, linking Lanzhou with Baotou, crosses the region. A highway has been built across the Yellow River at Yinchuan. On 16 December 1920, the Haiyuan earthquake, 8.6 magnitude, at 36.6°N 105.32°E / 36.6; 105.32, initiated a series of landslides that killed an estimated 200,000 people. Over 600 large loess landslides created more than 40 new lakes.
Sources: en.wikipedia.org
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.
The chain occurs in human plasma, saliva, and urine. Measured amounts are reported to fall with age. Copper binding by the sequence is treated as part of normal metal handling in tissue.
The bound copper(II) centre contributes to redox behaviour and to stability under physiological conditions. Free copper ions can participate in reactions that generate reactive species, while chelated metal is generally more controlled. The chain may also serve as a carrier for copper in experimental systems.
The colour depends on copper held in a specific coordination environment. When the complex dissociates or the peptide is cleaved, that environment changes and the visible absorption weakens.